{"id":2181,"company":{"country":"DK","currency":"EUR","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2015-01-28","marketCap":6151.92,"name":"Ascendis Pharma A/S","phone":"4570222244.0","outstanding":57.66,"symbol":"ASND","website":"https://ascendispharma.dk/","industry":"Biotechnology"},"price":119.3125,"year":2023,"month":12,"day":15,"weekday":"Friday","title":"Historical Stock Price Performance of Ascendis Pharma A/S during Significant Market Events","date":"2023-12-15","url":"/posts/2023/12/15/ASND","content":[{"section":"Dot-com Bubble (1997-2000)","text":"During the dot-com bubble in the late 1990s, several technology stocks experienced a significant rally followed by a crash. Ascendis Pharma was founded in 2006, so it did not have any historical stock price data during this market event."},{"section":"Global Financial Crisis (2007-2009)","text":"The global financial crisis that began in 2007 had a severe impact on the stock market. Ascendis Pharma did not go public until 2015, so it was not directly affected by this market event."},{"section":"COVID-19 Pandemic (2020)","text":"The COVID-19 pandemic had a major impact on global stock markets in 2020. Ascendis Pharma's stock price experienced volatility during this period, as investors reacted to the uncertainty and economic disruptions caused by the pandemic. However, the company's stock generally performed well, reflecting strong investor confidence in its pharmaceutical products and pipeline."},{"section":"Overall Market Rallies","text":"During overall market rallies, Ascendis Pharma's stock price has historically shown positive performance. This suggests that the company benefits from a favorable market environment and investor optimism."},{"section":"Overall Market Crashes","text":"During overall market crashes, Ascendis Pharma's stock price may experience temporary declines. However, the company's stock has shown resilience and tends to recover quickly, reflecting its strong fundamentals and the confidence of long-term investors."},{"section":"Long-Term Growth Trend","text":"Despite market events, Ascendis Pharma's stock has demonstrated a long-term growth trend, driven by successful product development and commercialization efforts. The company's focus on innovative therapies and its expanding pharmaceutical pipeline have attracted investors seeking long-term growth opportunities."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1702557120,"headline":"Oppenheimer, Wedbush say buy these biotech stocks for 2024","id":124517708,"image":"","symbol":"ASND","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3257143929"},{"category":"company","date":1702483628,"headline":"Ascendis Pharma A/S : Form 6-K","id":124493541,"image":"","symbol":"ASND","publisher":"Finnhub","summary":"Ascendis Pharma A/S Name, Registered Office and Objects of the Company: Article 1 ...","url":"https://finnhub.io/api/news?id=e8e44580114b8161713eb00fb3444e1bc32238e75508833a0184cf56564ffae5"},{"category":"company","date":1702470120,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Keros Therapeutics (KROS) and Cigna (CI)","id":124486733,"image":"","symbol":"ASND","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3254616612"},{"category":"company","date":1702470060,"headline":"Buy Rating for Ascendis Pharma Backed by Positive Regulatory Developments and Strong Sales Outlook","id":124504807,"image":"","symbol":"ASND","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3254615958"},{"category":"company","date":1702362108,"headline":"Ascendis Pharma - FDA Accepts for Review Resubmitted NDA for TransCon PTH in Adult Patients with Hypoparathyroidism","id":124455354,"image":"","symbol":"ASND","publisher":"Finnhub","summary":"Denmark - Ascendis Pharma A/S today announced that the U.S. Food \u0026 Drug Administration has accepted for review the Company s resubmitted New Drug Application for TransCon PTH for the treatment of...","url":"https://finnhub.io/api/news?id=27b52e50b9c211da85b8b82f4033bd48c43c81df497dcfddfc645a090b77376e"},{"category":"company","date":1702360560,"headline":"Buy Rating for Ascendis Pharma: Promising FDA Review and Market Opportunity","id":124467867,"image":"","symbol":"ASND","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3253073879"},{"category":"company","date":1702301400,"headline":"FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism","id":124438163,"image":"https://s.yimg.com/ny/api/res/1.2/Q8c5s_FadKhyBRfrM3OPQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDI-/https://media.zenfs.com/en/globenewswire.com/5f3a4374ff0a1aa63de2e8188b526ed4","symbol":"ASND","publisher":"Yahoo","summary":"– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food \u0026 Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism. The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act (PDUFA) goal date of May 14","url":"https://finance.yahoo.com/news/fda-accepts-review-resubmitted-nda-133000684.html"},{"category":"company","date":1702295820,"headline":"FDA accepts Ascendis resubmission of TransCon PTH market application","id":124449837,"image":"","symbol":"ASND","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251664323"},{"category":"company","date":1702284960,"headline":"Buy Rating on Ascendis Pharma Amidst FDA Resubmission and Promising Growth Prospects","id":124449838,"image":"","symbol":"ASND","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251417978"},{"category":"company","date":1702280400,"headline":"Ascendis Pharma announces FDA acceptance of resubmitted TransCon PTH NDA","id":124449840,"image":"","symbol":"ASND","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3251325391"},{"category":"company","date":1702015380,"headline":"Analysts Offer Insights on Healthcare Companies: Cigna (CI), Ascendis Pharma (ASND) and Evolent Health (EVH)","id":124388875,"image":"","symbol":"ASND","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247683925"},{"category":"company","date":1701925200,"headline":"Ascendant Resources Announces Non-Brokered Private Placement","id":124361153,"image":"","symbol":"ASND","publisher":"Accesswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3245725045"},{"category":"company","date":1701915120,"headline":"Echelon Wealth Partners Sticks to Its Buy Rating for Ascendant Resources Inc (ASND)","id":124397140,"image":"","symbol":"ASND","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246424390"},{"category":"company","date":1701748860,"headline":"Ascendant Appoints Banco Santander S.A. as Mandated Lead Arranger for Export Credit Agency Supported Project Financing at its Lagoa Salgada Project, Portugal","id":124342258,"image":"","symbol":"ASND","publisher":"Accesswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242851707"},{"category":"company","date":1701666120,"headline":"Ascendant Announces Closing of US$4 Million Funding for Its Lagoa Salgada VMS Project in Portugal","id":124283304,"image":"","symbol":"ASND","publisher":"Accesswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3240291863"}]}